[
  {
    "ts": null,
    "headline": "The Day Pharma’s Weight-Loss Gold Rush Intensified",
    "summary": "Lilly’s quarterly results Thursday, combined with Novo Nordisk’s unsolicited offer for a startup, confirm the $72 billion anti-obesity market is among pharma’s hottest.",
    "url": "https://finnhub.io/api/news?id=d657f5695c9ab44a0cf33b94028a1c553fc3d4771abca67a7397bcf0134c1c87",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761861600,
      "headline": "The Day Pharma’s Weight-Loss Gold Rush Intensified",
      "id": 137274979,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Lilly’s quarterly results Thursday, combined with Novo Nordisk’s unsolicited offer for a startup, confirm the $72 billion anti-obesity market is among pharma’s hottest.",
      "url": "https://finnhub.io/api/news?id=d657f5695c9ab44a0cf33b94028a1c553fc3d4771abca67a7397bcf0134c1c87"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Fires Back as Novo Nordisk Hijacks Its $8.5 Billion Metsera Deal",
    "summary": "A surprise bid sparks a fiery corporate showdown in the obesity drug race",
    "url": "https://finnhub.io/api/news?id=b48f55e77342a38401adc30e748287472c957c775c4a1e1f04b533c459d23e1c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761861031,
      "headline": "Pfizer Fires Back as Novo Nordisk Hijacks Its $8.5 Billion Metsera Deal",
      "id": 137275133,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "A surprise bid sparks a fiery corporate showdown in the obesity drug race",
      "url": "https://finnhub.io/api/news?id=b48f55e77342a38401adc30e748287472c957c775c4a1e1f04b533c459d23e1c"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Thursday Recap: Eli Lilly, Metsera, Navan, Chipotle",
    "summary": "↘️ Chipotle Mexican Grill (CMG): The restaurant chain posted a drop in net income and quarterly revenue missed forecasts. Chipotle said economic strains were turning customers away from its stores. Shares slid 18% Thursday.",
    "url": "https://finnhub.io/api/news?id=4bbf27c2793dff14c063655a65d34b638856f58305d8d7e6c5dd644e29ec3b57",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761856547,
      "headline": "Stocks to Watch Thursday Recap: Eli Lilly, Metsera, Navan, Chipotle",
      "id": 137271937,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "↘️ Chipotle Mexican Grill (CMG): The restaurant chain posted a drop in net income and quarterly revenue missed forecasts. Chipotle said economic strains were turning customers away from its stores. Shares slid 18% Thursday.",
      "url": "https://finnhub.io/api/news?id=4bbf27c2793dff14c063655a65d34b638856f58305d8d7e6c5dd644e29ec3b57"
    }
  },
  {
    "ts": null,
    "headline": "Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings.",
    "summary": "Alnylam stock took a hit Thursday after the biotech company said it received a subpoena from the U.S. government related to its four drugs.",
    "url": "https://finnhub.io/api/news?id=07775eda7d73a9db0f82ab20c41121ffcab4224032b67682e7bb0bacfa17644f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761855321,
      "headline": "Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings.",
      "id": 137269249,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Alnylam stock took a hit Thursday after the biotech company said it received a subpoena from the U.S. government related to its four drugs.",
      "url": "https://finnhub.io/api/news?id=07775eda7d73a9db0f82ab20c41121ffcab4224032b67682e7bb0bacfa17644f"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk takes on Pfizer in bid for obesity biotech Metsera",
    "summary": "STORY: A bidding war is heating up in the race for the next blockbuster obesity drug.Novo Nordisk on Thursday launched a surprise bid for U.S. biotech firm Metsera, hijacking an offer from Pfizer as the two jostle for advantage in the highly lucrative weight loss drug market.The news sent shares of Metsera, which were already up nearly 100% since January, soaring more than 23% on Thursday.Denmark's Novo Nordisk, maker of Wegovy and Ozempic, is offering up to $8.5 billion for Metsera.That tops Pfizer’s bid of $7.3 billion.Metsera says Novo’s offer is “superior” and has given Pfizer four days to respond.Pfizer said Novo had made a previous bid for Metsera that was rejected.It called Novo's revised offer \"reckless\" and bad for competition, adding it would \"pursue all legal avenues\" to defend its rights in the deal.Novo declined to comment on its previous bid, which was confirmed by several other sources.The company told Reuters its current offer - which values Metsera at $9 billion - underscored its commitment to investing in the US.Both Novo and Pfizer want access to Metsera's experimental lineup.They include a weight loss candidate drug that would only need to be injected once a month, unlike Novo's own Wegovy.Novo's offer comes a week after the company ousted most of its board members over concerns it was not moving fast enough in the obesity market, where it competes with main rival Eli Lilly.Meanwhile, shares of Lilly rose on Thursday after the company raised its full-year profit and revenue forecasts.Lilly, which makes injectable weight loss drugs Zepbound and Mounjaro, said its experimental weight-loss *pill* will be submitted to the U.S. Food and Drug Administration this quarter for review.",
    "url": "https://finnhub.io/api/news?id=71629cede9db08367f0c0ca272d53e34a23691e183c8729c928941bc649ad670",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761851002,
      "headline": "Novo Nordisk takes on Pfizer in bid for obesity biotech Metsera",
      "id": 137269250,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "STORY: A bidding war is heating up in the race for the next blockbuster obesity drug.Novo Nordisk on Thursday launched a surprise bid for U.S. biotech firm Metsera, hijacking an offer from Pfizer as the two jostle for advantage in the highly lucrative weight loss drug market.The news sent shares of Metsera, which were already up nearly 100% since January, soaring more than 23% on Thursday.Denmark's Novo Nordisk, maker of Wegovy and Ozempic, is offering up to $8.5 billion for Metsera.That tops Pfizer’s bid of $7.3 billion.Metsera says Novo’s offer is “superior” and has given Pfizer four days to respond.Pfizer said Novo had made a previous bid for Metsera that was rejected.It called Novo's revised offer \"reckless\" and bad for competition, adding it would \"pursue all legal avenues\" to defend its rights in the deal.Novo declined to comment on its previous bid, which was confirmed by several other sources.The company told Reuters its current offer - which values Metsera at $9 billion - underscored its commitment to investing in the US.Both Novo and Pfizer want access to Metsera's experimental lineup.They include a weight loss candidate drug that would only need to be injected once a month, unlike Novo's own Wegovy.Novo's offer comes a week after the company ousted most of its board members over concerns it was not moving fast enough in the obesity market, where it competes with main rival Eli Lilly.Meanwhile, shares of Lilly rose on Thursday after the company raised its full-year profit and revenue forecasts.Lilly, which makes injectable weight loss drugs Zepbound and Mounjaro, said its experimental weight-loss *pill* will be submitted to the U.S. Food and Drug Administration this quarter for review.",
      "url": "https://finnhub.io/api/news?id=71629cede9db08367f0c0ca272d53e34a23691e183c8729c928941bc649ad670"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer said to mull suing Novo Nordisk over Metsera bid",
    "summary": "Investing.com -- Pfizer is preparing to sue Metsera and potentially Novo Nordisk after the Danish drugmaker outbid Pfizer for the U.S. obesity biotech firm, according to a Semafor report Thursday.",
    "url": "https://finnhub.io/api/news?id=1e7cbb41d423c6afedff793feec9cd5608836b16d7de6a07bba3ceae4cd4c20d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761848198,
      "headline": "Pfizer said to mull suing Novo Nordisk over Metsera bid",
      "id": 137268879,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Investing.com -- Pfizer is preparing to sue Metsera and potentially Novo Nordisk after the Danish drugmaker outbid Pfizer for the U.S. obesity biotech firm, according to a Semafor report Thursday.",
      "url": "https://finnhub.io/api/news?id=1e7cbb41d423c6afedff793feec9cd5608836b16d7de6a07bba3ceae4cd4c20d"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Tries to Snatch a Weight-Loss Biotech From Pfizer. There Are Political Risks.",
    "summary": "Denmark’s Novo offers $56.50 a share in cash for Metsera, plus potentially a further $21.25 a share based on clinical and regulatory milestones.",
    "url": "https://finnhub.io/api/news?id=e39b7a090e0eec2068aba93b1d63ec949615e1b36d0ab6df8490635eef07c6d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761847860,
      "headline": "Novo Nordisk Tries to Snatch a Weight-Loss Biotech From Pfizer. There Are Political Risks.",
      "id": 137268688,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Denmark’s Novo offers $56.50 a share in cash for Metsera, plus potentially a further $21.25 a share based on clinical and regulatory milestones.",
      "url": "https://finnhub.io/api/news?id=e39b7a090e0eec2068aba93b1d63ec949615e1b36d0ab6df8490635eef07c6d2"
    }
  },
  {
    "ts": null,
    "headline": "CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy?",
    "summary": "CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.",
    "url": "https://finnhub.io/api/news?id=5015e2d52003dd5546789115235a693cdb4ad9f28aa0637a27858e98e513a52c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761847500,
      "headline": "CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy?",
      "id": 137269251,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.",
      "url": "https://finnhub.io/api/news?id=5015e2d52003dd5546789115235a693cdb4ad9f28aa0637a27858e98e513a52c"
    }
  },
  {
    "ts": null,
    "headline": "Meta Looks to Raise at Least $25 Billion From Bond Sale",
    "summary": "The anticipated size, which was according to people familiar with the matter, would make Meta’s deal one of the largest of 2025.  This year’s largest public investment-grade note sale was the $26 billion raised in March by Mars Inc., a candy maker, to help finance its purchase of Kellanova, a snack food company.  Meta is looking to issue notes in as many as six parts, ranging from five to 40 years in length, according to a person familiar with the matter who asked not to be identified as they’re not authorized to speak publicly.",
    "url": "https://finnhub.io/api/news?id=bcac45fdbd498ed04a8861eea7b7c2808e540b0c703e9bba4b921fc687e67d0d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761831455,
      "headline": "Meta Looks to Raise at Least $25 Billion From Bond Sale",
      "id": 137266418,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The anticipated size, which was according to people familiar with the matter, would make Meta’s deal one of the largest of 2025.  This year’s largest public investment-grade note sale was the $26 billion raised in March by Mars Inc., a candy maker, to help finance its purchase of Kellanova, a snack food company.  Meta is looking to issue notes in as many as six parts, ranging from five to 40 years in length, according to a person familiar with the matter who asked not to be identified as they’re not authorized to speak publicly.",
      "url": "https://finnhub.io/api/news?id=bcac45fdbd498ed04a8861eea7b7c2808e540b0c703e9bba4b921fc687e67d0d"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Gainers",
    "summary": "Guardant Health (GH) shares soared 26% amid heavy trading after the company reported overnight impro",
    "url": "https://finnhub.io/api/news?id=9fa2a18b689741f455aaa4093d9ca4573571a59322c8993aa53db74906eb920e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761845973,
      "headline": "Top Midday Gainers",
      "id": 137268882,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Guardant Health (GH) shares soared 26% amid heavy trading after the company reported overnight impro",
      "url": "https://finnhub.io/api/news?id=9fa2a18b689741f455aaa4093d9ca4573571a59322c8993aa53db74906eb920e"
    }
  },
  {
    "ts": null,
    "headline": "Bidding war rises over weight loss drug that could prevent ‘Ozempic face’",
    "summary": "Two of the world’s largest pharmaceutical companies are locked in a bidding war for the maker of a weight-loss drug that could help patients avoid succumbing to “Ozempic face”.",
    "url": "https://finnhub.io/api/news?id=8b4f6425452a7156b1d7c61996cdad966e594402e364e2fb4d50f40056b0bbce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761845465,
      "headline": "Bidding war rises over weight loss drug that could prevent ‘Ozempic face’",
      "id": 137268690,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Two of the world’s largest pharmaceutical companies are locked in a bidding war for the maker of a weight-loss drug that could help patients avoid succumbing to “Ozempic face”.",
      "url": "https://finnhub.io/api/news?id=8b4f6425452a7156b1d7c61996cdad966e594402e364e2fb4d50f40056b0bbce"
    }
  },
  {
    "ts": null,
    "headline": "Novo is no longer suppressing its M&A appetite",
    "summary": "Novo Nordisk, maker of weight-loss and diabetes jabs Ozempic and Wegovy, has a bold new boss in Maziar Mike Doustdar. His unusually aggressive...",
    "url": "https://finnhub.io/api/news?id=c6492871708af47fc7f9a873c89b79a85c95277b978f02d0eabe08f520ebe4e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761845028,
      "headline": "Novo is no longer suppressing its M&A appetite",
      "id": 137270639,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Novo Nordisk, maker of weight-loss and diabetes jabs Ozempic and Wegovy, has a bold new boss in Maziar Mike Doustdar. His unusually aggressive...",
      "url": "https://finnhub.io/api/news?id=c6492871708af47fc7f9a873c89b79a85c95277b978f02d0eabe08f520ebe4e2"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metsera",
    "summary": "Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera.",
    "url": "https://finnhub.io/api/news?id=8af455fa9e0d8536a775c224eb0d7d34578ac5959abe478c7e9e06b1b1b47dab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761844434,
      "headline": "Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metsera",
      "id": 137268691,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera.",
      "url": "https://finnhub.io/api/news?id=8af455fa9e0d8536a775c224eb0d7d34578ac5959abe478c7e9e06b1b1b47dab"
    }
  },
  {
    "ts": null,
    "headline": "Chipotle drags fast casual stocks lower, Meta reports raising $125B",
    "summary": "Yahoo Finance's John Hyland tracks today's top moving stocks and biggest market stories in this Market Minute, including Chipotle (CMG) shares dropping and dragging other fast-casual chains lower in response to the company's consumer pullback observations, Meta Platforms (META) reportedly raising $125 billion in bond sales, and Novo Nordisk (NVO) entering into a bidding war with Pfizer (PFE) for Metsera (MTSR). Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
    "url": "https://finnhub.io/api/news?id=d9ee47abe679aec603da38d98a4f3b1224f275d34a87139df26b5a4678f2fb9e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761844297,
      "headline": "Chipotle drags fast casual stocks lower, Meta reports raising $125B",
      "id": 137268619,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Yahoo Finance's John Hyland tracks today's top moving stocks and biggest market stories in this Market Minute, including Chipotle (CMG) shares dropping and dragging other fast-casual chains lower in response to the company's consumer pullback observations, Meta Platforms (META) reportedly raising $125 billion in bond sales, and Novo Nordisk (NVO) entering into a bidding war with Pfizer (PFE) for Metsera (MTSR). Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
      "url": "https://finnhub.io/api/news?id=d9ee47abe679aec603da38d98a4f3b1224f275d34a87139df26b5a4678f2fb9e"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Trump, Xi Reach Trade Agreement; Meta Shares Tumble After Analyst Downgrades, Price Target Cuts",
    "summary": "The Nasdaq Composite and S&P 500 Index were both down in late-morning trading Thursday, while the Do",
    "url": "https://finnhub.io/api/news?id=cb3b56bff55276bd3e6cd743f928fadfb34a06da89bfdd49766904db7c42304d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761839193,
      "headline": "Top Midday Stories: Trump, Xi Reach Trade Agreement; Meta Shares Tumble After Analyst Downgrades, Price Target Cuts",
      "id": 137268886,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Nasdaq Composite and S&P 500 Index were both down in late-morning trading Thursday, while the Do",
      "url": "https://finnhub.io/api/news?id=cb3b56bff55276bd3e6cd743f928fadfb34a06da89bfdd49766904db7c42304d"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk locks horns with Pfizer in late bid for Metsera",
    "summary": "While Pfizer called the bid “reckless”, Metsera disagrees, stating that it will review the “superior proposal”.",
    "url": "https://finnhub.io/api/news?id=a44f5b69ce013d4fc7ab53a1b90f7d535eac8c243b1829c48627e0a3cff81088",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761837831,
      "headline": "Novo Nordisk locks horns with Pfizer in late bid for Metsera",
      "id": 137268887,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "While Pfizer called the bid “reckless”, Metsera disagrees, stating that it will review the “superior proposal”.",
      "url": "https://finnhub.io/api/news?id=a44f5b69ce013d4fc7ab53a1b90f7d535eac8c243b1829c48627e0a3cff81088"
    }
  },
  {
    "ts": null,
    "headline": "UAE Interventional Cardiology Devices Forecast Report 2025: Market to Expand by Over $20 Billion by 2030 - Opportunities in Innovative Device Development, Government Initiatives, and Medical Tourism",
    "summary": "UAE Interventional Cardiology Devices Market UAE Interventional Cardiology Devices Market Dublin, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The \"UAE Interventional Cardiology Devices Market, By Region, Competition, Forecast and Opportunities, 2020-2030F\" report has been added to ResearchAndMarkets.com's offering.The UAE Interventional Cardiology Devices Market was valued at USD 58.25 Million in 2024, and is expected to reach USD 78.42 Million by 2030, rising at a CAGR of 5.08% The UAE interventional car",
    "url": "https://finnhub.io/api/news?id=896022b9f887dd94b1699b0950242ccf0cfd43cef45e93b6c0ac7fd20f6ee5db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761837720,
      "headline": "UAE Interventional Cardiology Devices Forecast Report 2025: Market to Expand by Over $20 Billion by 2030 - Opportunities in Innovative Device Development, Government Initiatives, and Medical Tourism",
      "id": 137268888,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "UAE Interventional Cardiology Devices Market UAE Interventional Cardiology Devices Market Dublin, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The \"UAE Interventional Cardiology Devices Market, By Region, Competition, Forecast and Opportunities, 2020-2030F\" report has been added to ResearchAndMarkets.com's offering.The UAE Interventional Cardiology Devices Market was valued at USD 58.25 Million in 2024, and is expected to reach USD 78.42 Million by 2030, rising at a CAGR of 5.08% The UAE interventional car",
      "url": "https://finnhub.io/api/news?id=896022b9f887dd94b1699b0950242ccf0cfd43cef45e93b6c0ac7fd20f6ee5db"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Thursday: Eli Lilly, Metsera, Navan, Microsoft",
    "summary": "↘️ Meta Platforms (META): The social-media company said it would “aggressively” raise spending to stay competitive in the artificial-intelligence arms race. That sent shares down more than 8.5% in premarket trading.",
    "url": "https://finnhub.io/api/news?id=f2fc75eb0410e65261398c78593125e759a0a1f2e24e638b65b11b190bcd491a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761827474,
      "headline": "Stocks to Watch Thursday: Eli Lilly, Metsera, Navan, Microsoft",
      "id": 137266379,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "↘️ Meta Platforms (META): The social-media company said it would “aggressively” raise spending to stay competitive in the artificial-intelligence arms race. That sent shares down more than 8.5% in premarket trading.",
      "url": "https://finnhub.io/api/news?id=f2fc75eb0410e65261398c78593125e759a0a1f2e24e638b65b11b190bcd491a"
    }
  },
  {
    "ts": null,
    "headline": "Obesity, diabetes treatments fuel Eli Lilly growth and spark bidding war",
    "summary": "Lilly said Thursday that its top-selling drugs, Mounjaro and Zepbound, brought in more than $10 billion combined during the recently completed third quarter.  Separately, Danish drugmaker Novo Nordisk announced plans to buy Metsera Inc. in a deal that could be worth up to $9 billion.",
    "url": "https://finnhub.io/api/news?id=e6c23c24894fdaf28bb6ccf21e3bc62f746e20ae622853bbc26548395ba21d7c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761835152,
      "headline": "Obesity, diabetes treatments fuel Eli Lilly growth and spark bidding war",
      "id": 137268696,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Lilly said Thursday that its top-selling drugs, Mounjaro and Zepbound, brought in more than $10 billion combined during the recently completed third quarter.  Separately, Danish drugmaker Novo Nordisk announced plans to buy Metsera Inc. in a deal that could be worth up to $9 billion.",
      "url": "https://finnhub.io/api/news?id=e6c23c24894fdaf28bb6ccf21e3bc62f746e20ae622853bbc26548395ba21d7c"
    }
  },
  {
    "ts": null,
    "headline": "BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View",
    "summary": "Bristol-Myers' strong Q3 results, powered by Opdivo, Reblozyl and Breyanzi, led to a revenue guidance boost despite legacy drug declines.",
    "url": "https://finnhub.io/api/news?id=5f1b0621ed88adc084f8b32cded96f37cc3256b1b726975b10c2abcc7f7cb852",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761834720,
      "headline": "BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View",
      "id": 137268891,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Bristol-Myers' strong Q3 results, powered by Opdivo, Reblozyl and Breyanzi, led to a revenue guidance boost despite legacy drug declines.",
      "url": "https://finnhub.io/api/news?id=5f1b0621ed88adc084f8b32cded96f37cc3256b1b726975b10c2abcc7f7cb852"
    }
  },
  {
    "ts": null,
    "headline": "Singapore Approves Latest Pfizer/BioNTech COVID-19 Vaccine for All Ages",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the most undervalued large cap stocks to buy right now. On October 24, Pfizer Singapore and BioNTech (NASDAQ:BNTX) announced that the Health Sciences Authority/HSA of Singapore approved their LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY LP.8.1; COVID-19 Vaccine, mRNA). The approval makes Singapore the first country in Southeast Asia to fully […]",
    "url": "https://finnhub.io/api/news?id=902824f44e3834b4385c07810353f78b18e60e47ceea6b8bedcd98da8695f5e8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761832606,
      "headline": "Singapore Approves Latest Pfizer/BioNTech COVID-19 Vaccine for All Ages",
      "id": 137266689,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the most undervalued large cap stocks to buy right now. On October 24, Pfizer Singapore and BioNTech (NASDAQ:BNTX) announced that the Health Sciences Authority/HSA of Singapore approved their LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY LP.8.1; COVID-19 Vaccine, mRNA). The approval makes Singapore the first country in Southeast Asia to fully […]",
      "url": "https://finnhub.io/api/news?id=902824f44e3834b4385c07810353f78b18e60e47ceea6b8bedcd98da8695f5e8"
    }
  },
  {
    "ts": null,
    "headline": "Alnylam Stock Has Already Doubled In 2025. But It Took A Hit On Earnings.",
    "summary": "Alnylam stock took a hit Thursday after the biotech company said it received a subpoena from the U.S. government related to its four drugs.",
    "url": "https://finnhub.io/api/news?id=78baf1033db2fd4034dfc08e0190f91c2e27375fc2d14a1e86a4616a00a7ec4f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761832166,
      "headline": "Alnylam Stock Has Already Doubled In 2025. But It Took A Hit On Earnings.",
      "id": 137266690,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Alnylam stock took a hit Thursday after the biotech company said it received a subpoena from the U.S. government related to its four drugs.",
      "url": "https://finnhub.io/api/news?id=78baf1033db2fd4034dfc08e0190f91c2e27375fc2d14a1e86a4616a00a7ec4f"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk's bid for Metsera, Eli Lilly boosts revenue outlook",
    "summary": "Morning Brief host Julie Hyman tracks several of the day's top trending stock tickers, including Novo Nordisk's (NVO) bidding war with Pfizer (PFE) over who acquires Metsera (MTSR), Merck (MRK) cutting the higher end of its sales guidance, and Eli Lilly (LLY) raising its full-year revenue forecast after topping third quarter earnings estimates. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
    "url": "https://finnhub.io/api/news?id=60f388828ad12dc7bb084b4b48253c813cc0b11a8bb2ae6b33b6fa57b259f68c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761830730,
      "headline": "Novo Nordisk's bid for Metsera, Eli Lilly boosts revenue outlook",
      "id": 137266482,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Morning Brief host Julie Hyman tracks several of the day's top trending stock tickers, including Novo Nordisk's (NVO) bidding war with Pfizer (PFE) over who acquires Metsera (MTSR), Merck (MRK) cutting the higher end of its sales guidance, and Eli Lilly (LLY) raising its full-year revenue forecast after topping third quarter earnings estimates. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
      "url": "https://finnhub.io/api/news?id=60f388828ad12dc7bb084b4b48253c813cc0b11a8bb2ae6b33b6fa57b259f68c"
    }
  },
  {
    "ts": null,
    "headline": "What Analyst Projections for Key Metrics Reveal About Pfizer (PFE) Q3 Earnings",
    "summary": "Evaluate the expected performance of Pfizer (PFE) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",
    "url": "https://finnhub.io/api/news?id=95f10e35c05ef30f2c44e839e89a23b079e746a8f30f561611be9241be30dfc2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761830107,
      "headline": "What Analyst Projections for Key Metrics Reveal About Pfizer (PFE) Q3 Earnings",
      "id": 137268892,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Evaluate the expected performance of Pfizer (PFE) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",
      "url": "https://finnhub.io/api/news?id=95f10e35c05ef30f2c44e839e89a23b079e746a8f30f561611be9241be30dfc2"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nodrisk stock dips on aggressive odder to buy Metsera, ’reckless’ says Pfizer",
    "summary": "Investing.com -- Novo Nordisk shares have slipped over 2% premarket on Thursday after the company made an unsolicited bid to acquire Metsera, a U.S. obesity drug developer, in a move BMO Capital described as “an over-the-top bid” that complicates Pfizer’s ongoing takeover attempt.",
    "url": "https://finnhub.io/api/news?id=99899c49cc7312e35e1d5fe027a7ae8d2d7e111a3da3520cab75b02ccd1331a2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761830011,
      "headline": "Novo Nodrisk stock dips on aggressive odder to buy Metsera, ’reckless’ says Pfizer",
      "id": 137266692,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Investing.com -- Novo Nordisk shares have slipped over 2% premarket on Thursday after the company made an unsolicited bid to acquire Metsera, a U.S. obesity drug developer, in a move BMO Capital described as “an over-the-top bid” that complicates Pfizer’s ongoing takeover attempt.",
      "url": "https://finnhub.io/api/news?id=99899c49cc7312e35e1d5fe027a7ae8d2d7e111a3da3520cab75b02ccd1331a2"
    }
  },
  {
    "ts": null,
    "headline": "Novo, Pfizer Square Off Over Metsera in Obesity-Drug Tussle",
    "summary": "Novo offered to buy Metsera Inc. for at least $6.5 billion, seeking to trump an earlier agreed deal with Pfizer.  Metsera called the new offer, which Bloomberg News reported earlier on Thursday, superior to the previous one from Pfizer that it had accepted last month.",
    "url": "https://finnhub.io/api/news?id=4962cf90915e7ff55b70bb8ea0edb6882d1a685e9166b60397ef52d6716e419d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761828862,
      "headline": "Novo, Pfizer Square Off Over Metsera in Obesity-Drug Tussle",
      "id": 137266693,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Novo offered to buy Metsera Inc. for at least $6.5 billion, seeking to trump an earlier agreed deal with Pfizer.  Metsera called the new offer, which Bloomberg News reported earlier on Thursday, superior to the previous one from Pfizer that it had accepted last month.",
      "url": "https://finnhub.io/api/news?id=4962cf90915e7ff55b70bb8ea0edb6882d1a685e9166b60397ef52d6716e419d"
    }
  },
  {
    "ts": null,
    "headline": "Metsera Becomes The Prize In Obesity's Biggest Bidding War",
    "summary": "Metsera, Inc. is at the center of a bidding war between Novo Nordisk and Pfizer, driving its stock up 20%. Learn more about MTSR stock here.",
    "url": "https://finnhub.io/api/news?id=65b03596b75afc3954855f55dcdcfc6c1b0e0a46803b65ecc0b793922985746d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761828843,
      "headline": "Metsera Becomes The Prize In Obesity's Biggest Bidding War",
      "id": 137268104,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1972337145/image_1972337145.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Metsera, Inc. is at the center of a bidding war between Novo Nordisk and Pfizer, driving its stock up 20%. Learn more about MTSR stock here.",
      "url": "https://finnhub.io/api/news?id=65b03596b75afc3954855f55dcdcfc6c1b0e0a46803b65ecc0b793922985746d"
    }
  },
  {
    "ts": null,
    "headline": "Update: Pfizer Calls Novo Nordisk's Metsera Acquisition Proposal 'Reckless'",
    "summary": "(Update with details throughout and Novo Nordisk's reply to a request for comment.) Pfizer (PFE)",
    "url": "https://finnhub.io/api/news?id=d85b396c1f03fb8ec4134a14dae08eb56242c4abd4dc7fcff986194f336b8f45",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761828491,
      "headline": "Update: Pfizer Calls Novo Nordisk's Metsera Acquisition Proposal 'Reckless'",
      "id": 137266694,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "(Update with details throughout and Novo Nordisk's reply to a request for comment.) Pfizer (PFE)",
      "url": "https://finnhub.io/api/news?id=d85b396c1f03fb8ec4134a14dae08eb56242c4abd4dc7fcff986194f336b8f45"
    }
  },
  {
    "ts": null,
    "headline": "Metsera Stock Soars. Novo Nordisk Looks to Outbid Pfizer for the Obesity-Drug Maker.",
    "summary": "Denmark’s Novo offers $56.50 a share in cash for Metsera, plus potentially a further $21.25 a share based on clinical and regulatory milestones.",
    "url": "https://finnhub.io/api/news?id=b2169b333ae1f2320ce396807182dbc04fbfebb0fe41ec42a9f55ca10599f5db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761827820,
      "headline": "Metsera Stock Soars. Novo Nordisk Looks to Outbid Pfizer for the Obesity-Drug Maker.",
      "id": 137266486,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Denmark’s Novo offers $56.50 a share in cash for Metsera, plus potentially a further $21.25 a share based on clinical and regulatory milestones.",
      "url": "https://finnhub.io/api/news?id=b2169b333ae1f2320ce396807182dbc04fbfebb0fe41ec42a9f55ca10599f5db"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk launches bidding war with Pfizer for obesity drugmaker Metsera",
    "summary": "Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited bid to acquire obesity treatment maker Metsera, topping an offer from US rival Pfizer which called the move \"reckless\".Pfizer called Novo Nordisk's offer a \"reckless and unprecedented proposal\".",
    "url": "https://finnhub.io/api/news?id=9afe6f8db7ccee9b1e4abfcf4ec242c482c714172a44e16a032167c7cf9c6913",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761826817,
      "headline": "Novo Nordisk launches bidding war with Pfizer for obesity drugmaker Metsera",
      "id": 137266491,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited bid to acquire obesity treatment maker Metsera, topping an offer from US rival Pfizer which called the move \"reckless\".Pfizer called Novo Nordisk's offer a \"reckless and unprecedented proposal\".",
      "url": "https://finnhub.io/api/news?id=9afe6f8db7ccee9b1e4abfcf4ec242c482c714172a44e16a032167c7cf9c6913"
    }
  },
  {
    "ts": null,
    "headline": "Mounjaro Powers Eli Lilly to Bumper Quarter of Earnings",
    "summary": "Eli Lilly reported higher profit and raised its outlook on surging demand for its weight-loss drugs, sending its shares higher.",
    "url": "https://finnhub.io/api/news?id=173c7a81ca0367f83cdacd719b8545bec433f73dceac5aa17f41f2268d72313c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761825420,
      "headline": "Mounjaro Powers Eli Lilly to Bumper Quarter of Earnings",
      "id": 137266493,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Eli Lilly reported higher profit and raised its outlook on surging demand for its weight-loss drugs, sending its shares higher.",
      "url": "https://finnhub.io/api/news?id=173c7a81ca0367f83cdacd719b8545bec433f73dceac5aa17f41f2268d72313c"
    }
  },
  {
    "ts": null,
    "headline": "10 Ideal 'Safer' Dividend Buys From 38 Of 68 October Graham Value All-Stars (GVAS)",
    "summary": "Discover top large-cap value stocks using YCharts & Ben Graham Formula. Find high-yield dividend picks for October 2024.",
    "url": "https://finnhub.io/api/news?id=152912af2c4a5df828f99db4b1d1d51ec3df8c40a3ebf45b674b1a6cd3ae9f7d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761825089,
      "headline": "10 Ideal 'Safer' Dividend Buys From 38 Of 68 October Graham Value All-Stars (GVAS)",
      "id": 137267929,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1138851310/image_1138851310.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover top large-cap value stocks using YCharts & Ben Graham Formula. Find high-yield dividend picks for October 2024.",
      "url": "https://finnhub.io/api/news?id=152912af2c4a5df828f99db4b1d1d51ec3df8c40a3ebf45b674b1a6cd3ae9f7d"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK) Q3 Earnings and Revenues Beat Estimates",
    "summary": "Merck (MRK) delivered earnings and revenue surprises of +9.32% and +1.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=d916535191d746202d0a1370720c01fe53a259a423202251568648e1144468a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761824702,
      "headline": "Merck (MRK) Q3 Earnings and Revenues Beat Estimates",
      "id": 137266608,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Merck (MRK) delivered earnings and revenue surprises of +9.32% and +1.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=d916535191d746202d0a1370720c01fe53a259a423202251568648e1144468a0"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Rises on Earnings as Investors Await Trump Drug Pricing Deal",
    "summary": "Shares of  Eli Lilly  climbed Thursday after the drugmaker reported third-quarter earnings that blew past expectations.  Eli Lilly  shares were up 5.6% to $859 in premarket trading Thursday.  Revenue from Mounjaro, the company’s Type 2 diabetes treatment, came in at $6.5 billion, above analysts’ consensus estimate of $5.4 billion.",
    "url": "https://finnhub.io/api/news?id=aa9ec888fb6e84a874954ce2054b156ea86b801fc68753380466c81534c6252d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761822780,
      "headline": "Eli Lilly Stock Rises on Earnings as Investors Await Trump Drug Pricing Deal",
      "id": 137266498,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Shares of  Eli Lilly  climbed Thursday after the drugmaker reported third-quarter earnings that blew past expectations.  Eli Lilly  shares were up 5.6% to $859 in premarket trading Thursday.  Revenue from Mounjaro, the company’s Type 2 diabetes treatment, came in at $6.5 billion, above analysts’ consensus estimate of $5.4 billion.",
      "url": "https://finnhub.io/api/news?id=aa9ec888fb6e84a874954ce2054b156ea86b801fc68753380466c81534c6252d"
    }
  },
  {
    "ts": null,
    "headline": "Metsera Receives Unsolicited Proposal from Novo Nordisk",
    "summary": "Metsera, Inc. (NASDAQ: MTSR) (\"Metsera\") today announced that its Board of Directors had determined, after consultation with its outside counsel and financial advisors, that an unsolicited proposal that Metsera received from Novo Nordisk A/S (Nasdaq Copenhagen: NOVO B) (\"Novo Nordisk\") to acquire Metsera (the \"Novo Nordisk Proposal\") constitutes a \"Superior Company Proposal\" as defined in Metsera's existing Merger Agreement with Pfizer (the \"Pfizer Merger Agreement\").",
    "url": "https://finnhub.io/api/news?id=272b6b7856ff85ba625f3efb7b41827e3c5780c5823dc09f1235e4dd464bde0b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761822420,
      "headline": "Metsera Receives Unsolicited Proposal from Novo Nordisk",
      "id": 137266700,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Metsera, Inc. (NASDAQ: MTSR) (\"Metsera\") today announced that its Board of Directors had determined, after consultation with its outside counsel and financial advisors, that an unsolicited proposal that Metsera received from Novo Nordisk A/S (Nasdaq Copenhagen: NOVO B) (\"Novo Nordisk\") to acquire Metsera (the \"Novo Nordisk Proposal\") constitutes a \"Superior Company Proposal\" as defined in Metsera's existing Merger Agreement with Pfizer (the \"Pfizer Merger Agreement\").",
      "url": "https://finnhub.io/api/news?id=272b6b7856ff85ba625f3efb7b41827e3c5780c5823dc09f1235e4dd464bde0b"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Addresses Proposal for Metsera",
    "summary": "NEW YORK, October 30, 2025--Pfizer Inc. (NYSE: PFE) is aware of the reckless and unprecedented proposal by Novo Nordisk A/S (NYSE: NVO) to acquire Metsera, Inc. (NASDAQ: MTSR). It is an attempt by a company with a dominant market position to suppress competition in violation of law by taking over an emerging American challenger. It is also structured in a way to circumvent antitrust laws and carries substantial regulatory and executional risk. The proposal is illusory and cannot qualify as a sup",
    "url": "https://finnhub.io/api/news?id=461728624d941103a28676bc596d38682c9545e1430a85c1a7fde26722e885af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761821820,
      "headline": "Pfizer Addresses Proposal for Metsera",
      "id": 137266701,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, October 30, 2025--Pfizer Inc. (NYSE: PFE) is aware of the reckless and unprecedented proposal by Novo Nordisk A/S (NYSE: NVO) to acquire Metsera, Inc. (NASDAQ: MTSR). It is an attempt by a company with a dominant market position to suppress competition in violation of law by taking over an emerging American challenger. It is also structured in a way to circumvent antitrust laws and carries substantial regulatory and executional risk. The proposal is illusory and cannot qualify as a sup",
      "url": "https://finnhub.io/api/news?id=461728624d941103a28676bc596d38682c9545e1430a85c1a7fde26722e885af"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera",
    "summary": "The Wegovy and Ozempic maker’s offer comes after Pfizer last month agreed to a lower deal to acquire the Nasdaq-listed obesity-drug developer.",
    "url": "https://finnhub.io/api/news?id=d9b84b939e3ac2967d6030ae77894e1eebd820733f2cd595bc141e66cca64fce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761821760,
      "headline": "Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera",
      "id": 137266702,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Wegovy and Ozempic maker’s offer comes after Pfizer last month agreed to a lower deal to acquire the Nasdaq-listed obesity-drug developer.",
      "url": "https://finnhub.io/api/news?id=d9b84b939e3ac2967d6030ae77894e1eebd820733f2cd595bc141e66cca64fce"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer and Roche place $10bn bets on obesity and liver disease therapies as Trump tightens grip on drug pricing and manufacturing",
    "summary": "The deals come against a backdrop of sweeping trade and pricing policies from Trump’s administration.",
    "url": "https://finnhub.io/api/news?id=8e9b7342bd0ef8570c68df9fddfa2e4a9566683ce434de9c4034a0bc76bdf89e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761820337,
      "headline": "Pfizer and Roche place $10bn bets on obesity and liver disease therapies as Trump tightens grip on drug pricing and manufacturing",
      "id": 137266703,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The deals come against a backdrop of sweeping trade and pricing policies from Trump’s administration.",
      "url": "https://finnhub.io/api/news?id=8e9b7342bd0ef8570c68df9fddfa2e4a9566683ce434de9c4034a0bc76bdf89e"
    }
  },
  {
    "ts": null,
    "headline": "Crinetics Pharmaceuticals: Its Post-FDA Approval Future",
    "summary": "Crinetics Pharmaceuticals (CRNX) stock has surged after FDA approval of Palsonify for acromegaly. Read the latest analysis on the stock here.",
    "url": "https://finnhub.io/api/news?id=6415483aa2073f974f5d89f167e6a8792f0323778e05ebed916a646140ab62e1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761819847,
      "headline": "Crinetics Pharmaceuticals: Its Post-FDA Approval Future",
      "id": 137267462,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2203542103/image_2203542103.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Crinetics Pharmaceuticals (CRNX) stock has surged after FDA approval of Palsonify for acromegaly. Read the latest analysis on the stock here.",
      "url": "https://finnhub.io/api/news?id=6415483aa2073f974f5d89f167e6a8792f0323778e05ebed916a646140ab62e1"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Wall Street Surprised By Q3 Strength, Keytruda Sales Surge",
    "summary": "Merck's Q3 2025 results saw huge growth in Winrevair and Capvaxive sales. Check out why I maintain my Strong Buy rating on MRK stock.",
    "url": "https://finnhub.io/api/news?id=781901023f2d2f6d302e52852d90fc1f00f9272f1f80893967bd0459c3622dc9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761816041,
      "headline": "Merck: Wall Street Surprised By Q3 Strength, Keytruda Sales Surge",
      "id": 137266210,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1389349379/image_1389349379.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Merck's Q3 2025 results saw huge growth in Winrevair and Capvaxive sales. Check out why I maintain my Strong Buy rating on MRK stock.",
      "url": "https://finnhub.io/api/news?id=781901023f2d2f6d302e52852d90fc1f00f9272f1f80893967bd0459c3622dc9"
    }
  },
  {
    "ts": null,
    "headline": "Prediction: Putting $1,000 Into These Dividend Stocks Could Pay Off for Years",
    "summary": "Investing in high-quality stocks with generous dividend payouts can help you gradually build substantial wealth.",
    "url": "https://finnhub.io/api/news?id=ec711ae38fa548c9c8e1c04057db6c0dee9b8a881a1debabbf52ff0541c547b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761812100,
      "headline": "Prediction: Putting $1,000 Into These Dividend Stocks Could Pay Off for Years",
      "id": 137266664,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Investing in high-quality stocks with generous dividend payouts can help you gradually build substantial wealth.",
      "url": "https://finnhub.io/api/news?id=ec711ae38fa548c9c8e1c04057db6c0dee9b8a881a1debabbf52ff0541c547b4"
    }
  },
  {
    "ts": null,
    "headline": "Novo tops Pfizer with $6.5B bid for Metsera",
    "summary": "Novo said its bid, which is worth $1.6 billion more than Pfizer's initial offer for the obesity drug specialist, would \"maximize the potential of Metsera's complementary portfolio and capabilities.\"",
    "url": "https://finnhub.io/api/news?id=b9c83fa2ce3ba54136f0296feb7650b60b4ae9a4dbff2889a425862e554e4399",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761810840,
      "headline": "Novo tops Pfizer with $6.5B bid for Metsera",
      "id": 137266705,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Novo said its bid, which is worth $1.6 billion more than Pfizer's initial offer for the obesity drug specialist, would \"maximize the potential of Metsera's complementary portfolio and capabilities.\"",
      "url": "https://finnhub.io/api/news?id=b9c83fa2ce3ba54136f0296feb7650b60b4ae9a4dbff2889a425862e554e4399"
    }
  }
]